Xalatan

How generic cyclosporine might affect optometry
How generic cyclosporine might affect optometryI foresee every dry eye script I write to be “changed” to generic cyclosporine. This means optometrists will be straddled with more burdensome prior authorizations and delays for the patients.
Managing ocular surface disease in patients with glaucomaTreating ocular surface disease may have an impact on the effectiveness of glaucoma treatment. Inder Paul Singh, MD, offers some strategies used in practice.
Novel dual agonist leads to notable IOP loweringThe drug ONO-9054 led to a greater reduction in IOP and a longer duration of reduction in a small clinical trial compared with latanoprost.
A bullish view: Navigating beyond glaucoma company mistakesCompanies specializing in glaucoma products can make billions of dollars, but only if they can find a path through a minefield of scientific, regulatory, and marketing hazards, according to Richard A. Lewis, MD.
Adherence to drug regimens may increase with genericsThe costs associated with medications for patients with glaucoma continue to have a significant effect on adherence. Making a switch from branded to generic drugs may make a difference for some patients in certain cases.